(Reuters) - A small trial of Cytokinetics Inc’s experimental drug for patients suffering from amyotropic lateral sclerosis, commonly known as Lou Gehrig’s disease, found that it improved muscle response in some patients. The patients in the Phase 2a trial were treated with either a single 500 mg dose of the drug, known as CK-2017357, or a 250 mg dose, as well as a placebo.
